Journal article
Treatment Outcomes of Depression: The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study
Journal of clinical psychopharmacology, Vol.34(3), pp.313-317
06/2014
DOI: 10.1097/JCP.0000000000000099
PMCID: PMC3992481
PMID: 24743713
Abstract
Background: The effectiveness of selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder (MDD) is controversial.
Aims: The clinical outcomes of subjects with nonpsychotic MDD were reported and compared with the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study outcomes to provide guidance on the effectiveness of SSRIs.
Methods: Subjects were treated with citalopram/escitalopram for up to 8 weeks. Depression was measured using the Quick Inventory of Depressive Symptomatology-Clinician Rated (QIDS-C16) and the 17-item Hamilton Depression Rating Scale.
Results: The group of subjects with at least 1 follow-up visit had a remission (QIDS-C16 ≤ 5) rate of 45.8% as well as a response (50% reduction in QIDS-C16) rate of 64.8%, and 79.9% achieved an improvement of 5 points or higher in QIDS-C16 score. The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study subjects were more likely to achieve a response than STAR*D study subjects. After adjustment for demographic factors, the response rates were not significantly different. When reporting the adverse effect burden, 60.5% of the subjects reported no impairment, 31.7% reported a minimal-to-mild impairment, and 7.8% reported a moderate-to-severe burden at the 4-week visit.
Conclusions: Patients contemplating initiating an SSRI to treat their MDD can anticipate a high probability of symptom improvement (79.9%) with a low probability that their symptoms will become worse. Patients with lower baseline severity have a higher probability of achieving remission. The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study replicates many findings of the first phase of the STAR*D study after controlling for the differences between the studies.
Details
- Title: Subtitle
- Treatment Outcomes of Depression: The Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study
- Creators
- David A Mrazek - Department of Psychiatry & Psychology, Mayo Clinic RochesterJoanna M Biernacka - Department of Psychiatry & Psychology, Mayo Clinic RochesterDonald E McAlpine - Department of Psychiatry & Psychology, Mayo Clinic RochesterJoachim Benitez - Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York Presbyterian—Allen Hospital, New York, New YorkVictor M Karpyak - Department of Psychiatry & Psychology, Mayo Clinic RochesterMark D Williams - Department of Psychiatry & Psychology, Mayo Clinic RochesterDaniel K Hall-Flavin - Department of Psychiatry & Psychology, Mayo Clinic RochesterPamela J Netzel - Department of Psychiatry & Psychology, Mayo Clinic RochesterVictoria Passov - U.S. Department of Defense, Department of Behavioral Health, Heidelberg, GermanyBarbara M Rohland - Department of Psychiatry & Psychology, Mayo Clinic RochesterGen Shinozaki - Sioux Falls VA Medical Center, Sioux Falls, South DakotaAstrid A Hoberg - Department of Psychiatry & Psychology, Mayo Clinic RochesterKaren A Snyder - Department of Psychiatry & Psychology, Mayo Clinic RochesterMaureen S Drews - Department of Information Technology, Mayo Clinic RochesterMichelle K Skime - Department of Psychiatry & Psychology, Mayo Clinic RochesterJessica A Sagen - Department of Psychiatry & Psychology, Mayo Clinic RochesterDaniel J Schaid - Department of Health Sciences Research, Mayo Clinic RochesterRichard Weinshilboum - Department of Molecular Pharmacology & Experimental Therapeutics; Mayo Clinic, Rochester, MinnesotaDavid J Katzelnick - Department of Psychiatry & Psychology, Mayo Clinic Rochester
- Resource Type
- Journal article
- Publication Details
- Journal of clinical psychopharmacology, Vol.34(3), pp.313-317
- DOI
- 10.1097/JCP.0000000000000099
- PMID
- 24743713
- PMCID
- PMC3992481
- NLM abbreviation
- J Clin Psychopharmacol
- ISSN
- 0271-0749
- eISSN
- 1533-712X
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Language
- English
- Date published
- 06/2014
- Academic Unit
- Psychiatry; Iowa Neuroscience Institute; Anesthesia; Neurosurgery
- Record Identifier
- 9984070263202771
Metrics
29 Record Views